Innoviva (Innoviva) Operating Cash Flow per Share : $1.92 (TTM As of Mar. 2024)

View and export this data going back to 2004. Start your Free Trial

What is Innoviva Operating Cash Flow per Share?

Innoviva's operating cash flow per share for the three months ended in Mar. 2024 was $0.44. Innoviva's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2024 was $1.92.

During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Innoviva was 40.40% per year. During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -16.20% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was -2.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Innoviva's Operating Cash Flow per Share or its related term are showing as below:

INVA' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -16.2 Med: 14.1 Max: 181.9
Current: -16.2

During the past 13 years, Innoviva's highest 3-Year average Operating Cash Flow per Share Growth Rate was 181.90% per year. The lowest was -16.20% per year. And the median was 14.10% per year.

INVA's 3-Year OCF Growth Rate is ranked worse than
71.8% of 1234 companies
in the Biotechnology industry
Industry Median: 3.45 vs INVA: -16.20

Innoviva Operating Cash Flow per Share Historical Data

The historical data trend for Innoviva's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innoviva Operating Cash Flow per Share Chart

Innoviva Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Operating Cash Flow per Share

Get a 7-Day Free Trial

2.27

2.76

3.86

2.12

1.62

Innoviva Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Operating Cash Flow per Share	Get a 7-Day Free Trial															0.29	0.58	0.51	0.39	0.44

Competitive Comparison of Innoviva's Operating Cash Flow per Share

For the Biotechnology subindustry, Innoviva's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innoviva's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innoviva's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Innoviva's Price-to-Operating-Cash-Flow falls into.

Innoviva Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Innoviva's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )	=	Cash Flow from Operations (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	141.064	/	86.876
	=	1.62

Innoviva's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Mar. 2024 )	=	Cash Flow from Operations (Q: Mar. 2024 )	/	Shares Outstanding (Diluted Average) (Q: Mar. 2024 )
	=	37.047	/	84.531
	=	0.44

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.92

Innoviva Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Innoviva's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Innoviva (Innoviva) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innoviva Inc (NAS:INVA) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

HVE:Germany HVE:Germany

Address

1350 Old Bayshore Highway, Suite 400, Burlingame, CA, USA, 94010

Website

https://www.inva.com

Innoviva Inc develops biopharmaceutical drugs in the antibiotic, respiratory, and digestive realms. Theravance's respiratory compounds are in late-stage trials for asthma and chronic obstructive pulmonary disease. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others. The firm collaborates with and receives funding from GlaxoSmithKline.

Executives

Marianne Zhen	officer: Chief Accounting Officer	C/O INNOVIVA, INC., 2000 SIERRA POINT PARKWAY, SUITE 500, BRISBANE CA 94005
Stephen Basso	officer: Chief Financial Officer	C/O INOZYME PHARMA, INC., 321 SUMMER STREET, SUITE 400, BOSTON MA 02210
Margaret Koziel	officer: Chief Medical Officer	C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Alexander J Denner	10 percent owner	C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Deborah Birx	director	3300 LOWELL STREET NW, WASHINGTON DC 20008
Sarissa Capital Management Lp	10 percent owner	660 STEAMBOAT ROAD, GREENWICH CT 06830
Pavel Raifeld	officer: Chief Executive Officer	1350 OLD BAYSHORE HIGHWAY, SUITE 400, BURLINGAME CA 94010
Sapna Srivastava	director	C/O MYOS CORPORATION, 45 HORSEHILL ROAD, SUITE 106, CEDAR KNOLLS NJ 07927
Larry G. Edwards	officer: CEO of La Jolla Pharmaceutical	C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472
Plc Glaxosmithkline	10 percent owner	980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Mark Dipaolo	director	660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Kostas D Odysseas	director	660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Sarah J. Schlesinger	director	C/O ARIAD PHARMACEUTICALS, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Jules Haimovitz	director	601 108TH AVENUE NE, SUITE 1200, BELLEVUE WA 98004
George Bickerstaff	director	C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511